Pulmonary Embolism After Sequential Use of Recombinant Factor VIIa and Activated Prothrombin Complex Concentrate in a Factor VIII Inhibitor Patient

Thromb Haemost 2002; 87(05): 925-926
DOI: 10.1055/s-0037-1613110

Letters to the Editor

Schattauer GmbH

Stephan B. Rosenfeld

¹Department of Internal Medicine, University of Iowa College of Medicine, Iowa City, IA

,

Karla K. Watkinson

²Department of Great Plains Regional Hemophilia Treatment Center, Iowa City, IA

,

Brad H. Thompson

³Department of Radiology, University of Iowa College of Medicine, Iowa City, IA

,

Donald E. Macfarlane

¹Department of Internal Medicine, University of Iowa College of Medicine, Iowa City, IA

²Department of Great Plains Regional Hemophilia Treatment Center, Iowa City, IA

,

Steven R. Lentz

¹Department of Internal Medicine, University of Iowa College of Medicine, Iowa City, IA

²Department of Great Plains Regional Hemophilia Treatment Center, Iowa City, IA

⁴Department of Veterans Affairs Medical Center, Iowa City, IA, USA

References
1 Kessler CM. New products for managing inhibitors to coagulation factors: a focus on recombinant factor VIIa concentrate. Curr Opin Hematol 2000; 07: 408-13.
2 Ewenstein BM. Continuous infusion of recombinant factor VIIa: continue or not?. Thromb Haemost 2001; 86: 942-4.
3 Aledort LM. Adverse reactions related to rVIIa?. Am J Hematol 2001; 67: 213.
4 van ’t Veer C, Golden NJ, Mann KG. Inhibition of thrombin generation by the zymogen facto VII: implications for the treatment of hemophilia A by factor VIIa. Blood 2000; 95: 1330-5.
5 Monroe DM, Hoffman M, Oliver JA, Roberts HR. A possible mechanism of activated factor VII independent of tissue factor. Blood Coag Fibrinol 1998; 09 Suppl: (Suppl. 01) S15-S20.
6 Key NS, Christie B, Henderson N, Nelsestuen GL. Possible therapeutic synergy between recombinant factor VIIa (rFVIIa) and prothrombin complex concentrate (PCC) in the treatment of hemophilia with inhibitors: evaluation of an in vitro test. Blood 2001; 96: 519a.